Identifying and Addressing Challenges in the Management and Treatment of Heart Failure With Preserved Ejection Fraction: Focusing on the Role of the Pharmacist

This activity was originally broadcast as a live virtual symposium during the 12^th Annual Directions in Pharmacy conference series.

Program Description

Despite evolving treatments for heart failure, it remains a significant public health problem. Patients with heart failure can experience chronic and debilitating complications affecting renal and metabolic functions, which contributes to hospitalizations and reduces patient quality of life. It is important for pharmacists to be aware of the complications associated with heart failure, especially for patients with heart failure with preserved ejection fraction (HFpEF). HFpEF presents with signs and symptoms of HF, but normal or near-normal left ventricular ejection fraction. Treatment strategies for HFpEF are often limited to diuretics, and management remains focused on treating associated conditions and relieving symptoms. This activity will review updated indications for available agents as well as specific agents under investigation for HFpEF to support treatment selection. Considerations for pharmacists assisting with transitions of care for patients with HFpEF will also be discussed, with a focus on guideline-recommended strategies and management of potential drug interactions and monitoring adherence.

Target audience: Retail pharmacists and health-system pharmacists

Type of activity: Application
Release date: June 20, 2022
Expiration date: June 20, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the incidence, pathophysiology, risk factors, and clinical presentation associated with heart failure with preserved ejection fraction (HFpEF) and how it differs from heart failure with reduced ejection fraction (HFrEF).
• Examine the clinical efficacy and safety data associated with agents recommended for the treatment of HFpEF as well as agents under investigation.
• Identify the role of the pharmacist in the treatment of HFpEF and in patient education.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-307-H01-P. The activity is available for CE credit through June 20, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS AQ Cardiology, CACP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms